Zydus agrees to pay $120 million to settle US patent dispute with Astellas | Company News
Zydus and its unit will also pay a prepaid royalty fee per unit on U.S. sales of generic Mirabegron from the deal date through September 2027 | Photo: X@ZydusUniverse
India’s Zydus Lifesciences and its US unit will pay $120 million to Astellas Pharma as part of a deal to resolve a patent dispute over the Japanese drugmaker’s bladder disorder drug Mirabegron, the Indian firm said on Thursday.
Zydus and its unit will also pay a prepaid royalty fee per unit on U.S. sales of generic Mirabegron from the date of the agreement through September 2027, the company said.
The agreement will enable the company to continue marketing generic Mirabegron in the U.S., Zydus said, adding that other terms and conditions of the agreement are confidential.
The announcement comes just days after local peer Lupine agreed to settle its dispute with Astellas over the same drug for $90 million.
At the time, analysts at brokerage Citi said the development could delay the entry of other “generic competitors” into the U.S. market and potentially provide Zydus and Lupine with a limited “period of competition.”
(Only the headline and image of this report may have been re-worked by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Publication Date: February 12, 2026 | 09:57 IST
